News
- Author:
- Laura Nikolaides
Publish date: September 28, 2017
The probability of HER2 status discordance decreased with increasing age, but increased with primary tumors that were hormone-receptor positive, hi...
News
- Author:
- Laura Nikolaides
Publish date: September 14, 2017
Bevacizumab-awwb is approved for the treatment of adults with certain colorectal, lung, brain, kidney, and cervical cancers.
News
- Author:
- Laura Nikolaides
Publish date: September 11, 2017
ASCO recommends oncologists establish care goals and address cost of care with each patient.
News
- Author:
- Laura Nikolaides
Publish date: August 16, 2017
Phase 3 results for sunitinib as adjuvant treatment for high risk RCC have been mixed.
News
- Author:
- Laura Nikolaides
Publish date: August 2, 2017
The indication includes patients aged 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal c...
News
- Author:
- Laura Nikolaides
Publish date: August 2, 2017
Acalabrutinib for treatment of patients with mantle cell lymphoma has been granted priority review by the FDA.
News
- Author:
- Laura Nikolaides
Publish date: July 18, 2017
A new approval may help keep HER2+ breast cancer from coming back.
News
- Author:
- Laura Nikolaides
Publish date: June 23, 2017
The FDA also approved a next-generation sequencing test to detect BRAF and other mutations from a single tissue specimen.
News
- Author:
- Laura Nikolaides
Publish date: June 22, 2017
Approval provides patients a subcutaneous route for rituximab, significantly reducing the administration time.
Video
- Author:
- Laura Nikolaides
Publish date: June 20, 2017
Expert provides take-home messages on pertuzumab, PARP inhibitors, and CDK4/6 inhibitors.
Video
- Author:
- Laura Nikolaides
Publish date: June 16, 2017
SEER data on metastatic breast cancer includes only those diagnosed de novo and not women who were diagnosed following a metastatic recurrence of e...
Video
- Author:
- Laura Nikolaides
Publish date: June 14, 2017
CHICAGO – A breast cancer advocate discusses mixed response from physicians and barriers to trial participation faced by patients.
News
- Author:
- Laura Nikolaides
Publish date: May 18, 2017
Pembrolizumab is the third checkpoint inhibitor approved for bladder cancer this month.
News
- Author:
- Laura Nikolaides
Publish date: May 12, 2017
The approval was based on an improved overall response rate and progression-free survival in a cohort of 123 patients.
News
- Author:
- Laura Nikolaides
Publish date: May 9, 2017
The drug is approved for second-line use following platinum-containing chemotherapy.
